Becton, Dickinson and Company

BDX Healthcare Medical Instruments & Supplies

Becton, Dickinson and Company’s revenue for fiscal 2025 (year ended September 2025) was $21.8 billion, up 8.24% from fiscal 2024.

Revenue
−9.55%
EPS
−31.5%
Free cash flow
−31.6%
Total debt
−22.9%

Quarter to June 2026, against a year earlier

212.96 3.77 +1.80%
Market cap
$58.2B
P/E
64.1×
Fwd P/E
39.2×
Dividend yield
1.87%
F-score
7/9
Altman Z
1.85
Beneish M
−2.64
Dividend safety
67/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

25.65 25.34 39.81 45.58
P/S ratio
1.97 2.02 2.07 2.00
P/FCF ratio
16.14 16.86 12.63 12.98
P/Operating CF
23.27 67.51 65.76 53.59
P/B ratio
1.70 1.75 1.83 1.70
EV/Sales
2.74 2.75 2.71 2.60
EV/EBITDA
11.89 11.71 11.92 11.39
EV/FCF
22.44 22.90 16.54 16.93
Current Ratio
1.11 1.05 0.94 0.87
Net Debt/EBITDA
9.58 13.63 22.33 10.32
Debt/Equity
0.69 0.67 0.61 0.55
Earnings Yield
3.90% 3.95% 2.51% 2.19%
Free Cash Flow Yield
6.20% 5.93% 7.92% 7.70%
Free Cash Flow per Share
5.13 1.92 1.95 2.30
Book value per Share
88.27 88.53 85.99 88.85
Free Cash Flow
1,475.00 549.00 546.00 633.00
EV/EBIT
23.24 22.52 24.25 23.50
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026